A Phase 1, Open-label Taste Assessment Study of Vanzacaftor/Tezacaftor/Deutivacaftor in Healthy Adult Panelists
Latest Information Update: 21 May 2024
At a glance
- Drugs Deutivacaftor/tezacaftor/vanzacaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Vertex Pharmaceuticals
Most Recent Events
- 15 May 2024 Status changed from recruiting to completed.
- 05 Apr 2024 Status changed from not yet recruiting to recruiting.
- 12 Mar 2024 New trial record